Nanobiotix Updates Voting Rights and Share Capital Details

Barchart·10/16/2025 05:38:06

Listen to the news

Elevate Your Investing Strategy:

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Nanobiotix ( (NBTX) ) has shared an update.

On October 15, 2025, Nanobiotix announced its voting rights and share capital details as of September 30, 2025. The company reported 48,237,471 outstanding shares, with 50,318,257 theoretical voting rights and 50,296,139 exercisable voting rights. This update is crucial for stakeholders to understand the company’s current shareholder structure and voting power distribution.

The most recent analyst rating on (NBTX) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.

Spark’s Take on NBTX Stock

According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.

Nanobiotix’s stock score is primarily impacted by significant financial instability, marked by declining revenues and negative profitability. However, the stock’s strong technical momentum provides a counterbalance, suggesting potential short-term interest despite the company’s broader financial challenges. Valuation concerns persist due to the negative P/E ratio, reflecting non-profitability.

To see Spark’s full report on NBTX stock, click here.

More about Nanobiotix

Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, focusing on innovative, physics-based therapeutic solutions. Founded in 2003, the company is listed on Euronext Paris and the Nasdaq Global Select Market, with subsidiaries in the United States. Nanobiotix owns over 25 patent families related to nanotechnology platforms in oncology, bioavailability, biodistribution, and central nervous system disorders.

Average Trading Volume: 60,089

Technical Sentiment Signal: Buy

Current Market Cap: $1.36B

Learn more about NBTX stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure Report an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English

Nanobiotix Updates Voting Rights and Share Capital Details

Elevate Your Investing Strategy:

Trending Articles